DSM Execute Multimillion Dollar Agreement for Development of Second Generation Biofuels

Royal DSM N.V., the global Life Sciences and Materials Sciences company today announced the execution of a multimillion dollar cooperative funding agreement with the US Department of Energy to underwrite a portion of research and development costs aimed at enabling “second generation” biofuels from non-food feedstocks.

In February 2008, a consortium led by DSM that includes Abengoa Bioenergy New Technologies, Los Alamos National Laboratory and Sandia National Laboratory was awarded USD 7.4 million by the Department of Energy toward a proposed USD 33 million program to conduct cost effective enzyme development focused on finding applications in cellulose-based biorefineries for the production of advanced biofuels bio-based products. As part of its strategy to fully establish industrial biotechnology as an alternative to traditional petrochemical manufacturing, DSM has committed to funding the majority of the project costs and to creating new highly skilled “green collar” jobs at its Belvidere, NJ facility. The research will help further the Department of Energy’s goal of making cellulosic ethanol cost-competitive with gasoline by 2012, and the standard set out in the Energy Independence and Security Act of 2007 calling for the U.S. to produce 36 billion gallons of biofuel by the year 2022.

“This initiative is a major step forward in DSM’s mission to make Industrial Biotechnology a competitive alternative for manufacturing sustainable and renewable fuel, material and medicine,” says Feike Sijbesma, DSM CEO. “Through our collaboration with government and other industry leaders, we will be able to accelerate cellulosic biofuels R&D, help make New Jersey a powerhouse in the quest for sustainable energy independence, and create high-value green collar jobs within the state.”

DSM and the Department of Energy, through their Cooperative Agreement, will work during the next four years to develop cost efficient enzymes to allow for the manufacturing of commercial quantities of second generation biofuel. This work has already begun, and will continue at DSM’s facility in New Jersey, and around the world.

“This federal funding helps create green collar jobs here in New Jersey and promotes energy independence - goals we need to achieve to spur our economy and break our addiction to oil,” said U.S. Senator Robert Menendez. “I am proud that this project will help place the Garden State at the forefront in the creation of low-cost and advanced biofuels, fuels which will aid family budgets and our state’s economy. I look forward to seeing this project come to fruition, contributing to the ‘greening’ of our state in a way that does not rely on food sources.”

US Senator Fran Lautenberg added, "Innovative companies right here in New Jersey are leading the way in developing environmentally sound fuels to help usher in a new energy future. I will continue to work to support New Jersey's renewable fuels in Washington to help bring needed green-collar jobs to the state—and help the environment."

Proprietary enzymes that make it possible to hydrolyze cellulose and xylose from various plant residues are available today, but a significant volume of R&D and collaborative partnerships are still needed to make the process commercially viable. DSM’s corporate history, with more than 100 years of experience in enzymes, yeast technology and industrial fermentation, together with its integration of chemical engineering and biotechnology competencies in a single organization, make the company uniquely qualified to overcome the technical obstacles currently encountered in the pursuit of commercial-scale second generation biofuels.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.